# Ribon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ribon-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.ribontx.com
- Total disclosed funding: $51M
- Latest round: Series B (Jul 14, 2021)
- Investors on record: 14

## About

Ribon Therapeutics, Inc., based in the US, is a biotechnology company that focuses on developing innovative small molecule therapies targeting various diseases, particularly in oncology.Founded in 2015 and headquartered in Cambridge, US, Ribon Therapeutics, Inc. is dedicated to advancing therapeutic solutions in oncology. The company has secured a total of 5 deals, with their most recent funding round occurring on December 22, 2022. In this Series B round, Ribon Therapeutics raised USD 25.00 mn from Pfizer Inc., bringing their total amount raised to USD 25.00 mn and their current valuation to USD 250.26 mn. The company was founded by W Kraus, with Prakash Raman and Victoria Richon serving as current executive leaders.Ribon Therapeutics develops a range of small molecule therapies aimed at treating various types of cancer. Their focus is on innovative solutions that specifically target the mechanisms of disease, enhancing the efficacy of cancer treatments and improving patient outcomes. The company aims to address significant unmet medical needs within the oncology sector, offering potential advancements in personalized medicine, particularly through their first small molecule programs.Ribon Therapeutics generates revenue through collaborations and partnerships in the biotechnology sector, including funding from strategic investors such as Pfizer Inc. Their revenue structure is aligned with the ongoing development of their innovative therapeutic programs, designed to create sustainable financial support as their products progress through clinical trials.Following their Series B funding round on December 22, 2022, where they raised USD 25.00 mn from Pfizer Inc., Ribon Therapeutics plans to utilize this capital to further develop its first small molecule programs in oncology. The company is focused on expanding its research and development initiatives, striving to enhance its product pipeline and potentially launch new therapies in the coming years. Ribon Therapeutics is also exploring opportunities to enter new markets and geographic regions to broaden its reach in the biotech industry.

## Funding rounds

- Series B, Jul 14, 2021, $25M — US Venture Partners, Novartis Venture Fund, Johnson & Johnson Innovation, Peregrine Ventures, The Column Group, OUP (Osage University Partners), GV, Bristol-Myers Squibb Company, AbbVie Ventures, Takeda Ventures, Deerfield Management, Monashee Investment Management, Euclidean Capital, Avego Bioscience Capital
- Series B, Jan 4, 2019, $25M — US Venture Partners, Novartis Venture Fund, Johnson & Johnson Innovation, The Column Group, OUP (Osage University Partners), Takeda Ventures, Deerfield Management, Bristol-Myers Squibb Company, Euclidean Capital

## Investors

- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- Bristol-Myers Squibb Company — Series B
- Euclidean Capital — Series B
- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series B
- Monashee Investment Management — Series B
- Avego Bioscience Capital — Series B